A multi-center, open-label extension study of subcutaneous secukinumab to evaluate the long-term
The purpose of this extension study is to assess the safety and tolerability of secukinumab when administered long-term in patients with polymyalgia rheumatica.
- Investigator
- Roland Staud
- Status
- Accepting Candidates
- Ages
- 50 Years - 100 Years
- Sexes
- All
REPLENISH
The purpose of this study is to demonstrate the efficacy and safety of secukinumab 300 milligram (mg) and 150 mg administered subcutaneously (s.c.) for 52 weeks in combination with prednisone tapered over 24 weeks in adult participants with PMR who…
- Investigator
- Roland Staud
- Status
- Accepting Candidates
- Ages
- 50 Years - 100 Years
- Sexes
- All